Clinical Trial Update: A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

A study of Enfortumab Vedotin, alone or with other therapies, for urothelial cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureteral Cancer
• Urethral Cancer
• Urothelial Cancer

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 1, Phase 2 | Status: TERMINATED